Open-mkt buys · 90d
—
0 trades · 0 insiders
Open-mkt sales · 90d
—
0 trades · 0 insiders
Net · 90d
$0
Insiders on file
10
Daily buy vs sell · 90 days
No data yet.
Insiders
| Insider | Role | Trades | Bought | Sold | Last trade |
|---|---|---|---|---|---|
| Manning Meredith | Director | 2 | $0 | $0 | 2026-10-28 |
| Jermasek Douglas | EVP, Corporate Strategy | 13 | $0 | $0 | 2026-05-14 |
| Kenkare-Mitra Sara | Director | 8 | $0 | $0 | 2026-05-14 |
| Gupta Shalabh K. | CEO | 14 | $0 | $0 | 2026-05-14 |
| Gupta Pramod | EVP, Pharmaceuticals and BD | 14 | $0 | $0 | 2026-05-14 |
| Laumas Sandeep | Director | 8 | $0 | $0 | 2026-05-14 |
| Townsend John | Chief Financial Officer | 8 | $0 | $0 | 2026-05-14 |
| Aggarwal Gaurav | Director | 15 | $0 | $0 | 2025-08-25 |
| Ryan John L | Director | 1 | $0 | $0 | 2023-09-05 |
| Schiller Brigitte | Director | 3 | $12.4K | $0 | 2022-07-15 |
Trade history
| Insider | Role | Code | Trade | Filed | Shares | Price | Value | Owned after | |
|---|---|---|---|---|---|---|---|---|---|
| Manning Meredith | Director | A Award deriv | 2026-10-28 | 2026-10-29 | 27,000 | — | $0 | 27,000 | SEC↗ |
| Manning Meredith | Director | A Award deriv | 2026-10-28 | 2026-10-29 | 3,350 | — | $0 | 3,350 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-07-28 | 47,941 | — | $0 | 47,941 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-07-28 | 47,941 | — | $0 | 47,941 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-05-18 | 42,100 | — | $0 | 126,300 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-05-18 | 84,200 | — | $0 | 84,200 | SEC↗ |
| Townsend John | CFO | A Award deriv | 2026-05-14 | 2026-05-20 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2026-05-14 | 2026-05-20 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Jermasek Douglas | EVP, Corporate Strategy | A Award deriv | 2026-05-14 | 2026-05-20 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-05-21 | 84,200 | — | $0 | 84,200 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-05-21 | 42,100 | — | $0 | 126,300 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2026-05-14 | 2026-05-21 | 762,200 | — | $0 | 762,200 | SEC↗ |
| Jermasek Douglas | EVP, Corporate Strategy | A Award deriv | 2026-05-14 | 2026-06-15 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Townsend John | CFO | A Award deriv | 2026-05-14 | 2026-06-15 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2026-05-14 | 2026-06-15 | 169,500 | — | $0 | 169,500 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-06-15 | 84,200 | — | $0 | 84,200 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-06-15 | 42,100 | — | $0 | 126,300 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-06-15 | 42,100 | — | $0 | 126,300 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-06-15 | 84,200 | — | $0 | 84,200 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2026-05-14 | 2026-06-15 | 762,200 | — | $0 | 762,200 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2026-05-14 | 2026-07-28 | 47,941 | — | $0 | 47,941 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2026-05-14 | 2026-07-28 | 47,941 | — | $0 | 47,941 | SEC↗ |
| Aggarwal Gaurav | Director | D To issuer deriv | 2025-08-25 | 2025-08-26 | 3,199 | $1000.00 | $3.20M | 0 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion | 2025-08-25 | 2025-08-26 | 652,900 | — | $0 | 1,789,915 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2025-07-28 | 2025-07-30 | 10,000 | — | $0 | 215,500 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2025-07-28 | 2025-07-30 | 90,000 | — | $0 | 301,986 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2025-07-28 | 2025-07-30 | 10,000 | — | $0 | 101,557 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2025-07-28 | 2025-07-30 | 325,000 | — | $0 | 968,951 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2025-07-28 | 2025-07-30 | 21,200 | — | $0 | 39,200 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2025-07-28 | 2025-07-30 | 21,200 | — | $0 | 41,286 | SEC↗ |
| Aggarwal Gaurav | Director | A Award deriv | 2025-07-28 | 2025-07-30 | 21,200 | — | $0 | 39,200 | SEC↗ |
| Aggarwal Gaurav | Director | D To issuer deriv | 2025-02-18 | 2025-02-19 | 686 | $1000.00 | $686.0K | 3,119 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion | 2025-02-18 | 2025-02-19 | 1,400,000 | — | $0 | 11,370,152 | SEC↗ |
| Aggarwal Gaurav | Director | D To issuer deriv | 2024-10-09 | 2024-10-10 | 2,695 | $1000.00 | $2.69M | 3,885 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion | 2024-10-09 | 2024-10-10 | 5,500,000 | — | $0 | 9,970,152 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2024-08-12 | 2024-08-14 | 232,868 | — | $0 | 6,439,505 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2024-08-12 | 2024-08-14 | 81,750 | — | $0 | 2,055,000 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2024-08-12 | 2024-08-14 | 40,256 | — | $0 | 915,565 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2024-08-12 | 2024-08-14 | 81,750 | — | $0 | 2,119,862 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2024-04-15 | 2024-04-17 | 1,319,583 | — | $0 | 6,206,637 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2024-04-15 | 2024-04-17 | 463,250 | — | $0 | 2,038,112 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2024-04-15 | 2024-04-17 | 463,250 | — | $0 | 1,973,250 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2024-04-15 | 2024-04-17 | 228,119 | — | $0 | 875,309 | SEC↗ |
| Aggarwal Gaurav | Director | A Award deriv | 2023-09-05 | 2023-09-07 | 180,000 | — | $0 | 180,000 | SEC↗ |
| Ryan John L | Director | A Award deriv | 2023-09-05 | 2023-09-07 | 112,147 | — | $0 | 123,775 | SEC↗ |
| Kenkare-Mitra Sara | Director | A Award deriv | 2023-09-05 | 2023-09-07 | 180,000 | — | $0 | 180,000 | SEC↗ |
| Laumas Sandeep | Director | A Award deriv | 2023-09-05 | 2023-09-07 | 189,236 | — | $0 | 200,864 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2023-08-28 | 2023-08-30 | 1,355,000 | — | $0 | 1,510,000 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2023-08-28 | 2023-08-30 | 570,329 | — | $0 | 647,190 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2023-08-28 | 2023-08-30 | 4,684,775 | — | $0 | 4,988,798 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2023-08-28 | 2023-08-30 | 1,355,000 | — | $0 | 1,574,862 | SEC↗ |
| Gupta Shalabh K. | CEO | M Exercise deriv | 2023-07-11 | 2023-07-13 | 72,047 | — | $0 | 72,047 | SEC↗ |
| Gupta Shalabh K. | CEO | M Exercise deriv | 2023-07-11 | 2023-07-13 | 50 | $1000.00 | $50.0K | 0 | SEC↗ |
| Gupta Shalabh K. | CEO | M Exercise deriv | 2023-07-11 | 2023-07-13 | 79,252 | — | $0 | 79,252 | SEC↗ |
| Gupta Shalabh K. | CEO | M Exercise deriv | 2023-07-11 | 2023-07-13 | 115,275 | — | $0 | 115,275 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | M Exercise deriv | 2023-07-11 | 2023-07-13 | 28,818 | — | $0 | 28,818 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | M Exercise deriv | 2023-07-11 | 2023-07-13 | 20 | $1000.00 | $20.0K | 0 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | M Exercise deriv | 2023-07-11 | 2023-07-13 | 31,700 | — | $0 | 31,700 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | M Exercise deriv | 2023-07-11 | 2023-07-13 | 46,110 | — | $0 | 46,110 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | M Exercise deriv | 2023-07-11 | 2023-07-13 | 72,047 | — | $0 | 72,047 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | M Exercise deriv | 2023-07-11 | 2023-07-13 | 79,252 | — | $0 | 79,252 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | M Exercise deriv | 2023-07-11 | 2023-07-13 | 115,275 | — | $0 | 115,275 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | M Exercise deriv | 2023-07-11 | 2023-07-13 | 50 | $1000.00 | $50.0K | 0 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion deriv | 2023-07-11 | 2023-07-13 | 12,802,388 | — | $0 | 12,802,388 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion deriv | 2023-07-11 | 2023-07-13 | 11,638,534 | — | $0 | 11,638,534 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion deriv | 2023-07-11 | 2023-07-13 | 18,621,655 | — | $0 | 18,621,655 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion deriv | 2023-07-11 | 2023-07-13 | 13,429,000 | — | $0 | 13,429,000 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion deriv | 2023-07-11 | 2023-07-13 | 8,077 | $1000.00 | $8.08M | 0 | SEC↗ |
| Gupta Shalabh K. | CEO | M Exercise | 2023-07-11 | 2023-07-13 | 104,612 | — | $0 | 2,527,449 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | M Exercise | 2023-07-11 | 2023-07-13 | 41,845 | — | $0 | 41,845 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | M Exercise | 2023-07-11 | 2023-07-13 | 104,612 | — | $0 | 175,012 | SEC↗ |
| Aggarwal Gaurav | Director | C Conversion | 2023-07-11 | 2023-07-13 | 3,470,152 | — | $0 | 3,470,152 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2023-03-08 | 2023-03-09 | 50 | $1000.00 | $50.0K | 50 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2023-03-08 | 2023-03-09 | 20 | $1000.00 | $20.0K | 20 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2023-03-08 | 2023-03-09 | 50 | $1000.00 | $50.0K | 50 | SEC↗ |
| Aggarwal Gaurav | Director | A Award deriv | 2023-03-08 | 2023-03-09 | 8,077 | $1000.00 | $8.08M | 8,077 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2022-11-21 | 2022-11-23 | 86,000 | — | $0 | 202,279 | SEC↗ |
| Jermasek Douglas | EVP of Corporate Strategy | A Award deriv | 2022-11-21 | 2022-11-23 | 55,000 | — | $0 | 155,000 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2022-11-21 | 2022-11-23 | 35,000 | — | $0 | 76,861 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2022-11-21 | 2022-11-23 | 28,000 | — | $0 | 219,862 | SEC↗ |
| Schiller Brigitte | Director | M Exercise deriv | 2022-07-15 | 2022-08-30 | 26,738 | — | $0 | 0 | SEC↗ |
| Schiller Brigitte | Director | M Exercise | 2022-07-15 | 2022-08-30 | 26,738 | — | $0 | 26,738 | SEC↗ |
| Schiller Brigitte | Director | P Buy | 2022-05-16 | 2022-05-17 | 15,000 | $0.83 | $12.4K | 15,000 | SEC↗ |
| Gupta Pramod | EVP, Pharmaceuticals and BD | A Award deriv | 2021-07-15 | 2021-07-26 | 34,884 | — | $0 | 191,862 | SEC↗ |
| Townsend John | Chief Financial Officer | A Award deriv | 2021-07-15 | 2021-07-26 | 18,605 | — | $0 | 41,861 | SEC↗ |
| Gupta Shalabh K. | CEO | A Award deriv | 2021-07-15 | 2021-07-26 | 116,279 | — | $0 | 218,023 | SEC↗ |